Dr. Samir Kapadia
Claim this profileCleveland Clinic
Studies Mitral Regurgitation
Studies Mitral Valve Regurgitation
18 reported clinical trials
25 drugs studied
About Samir Kapadia
Education:
- Graduated with an MBBS (Bachelor of Medicine, Bachelor of Surgery) from Smt. NHL Municipal Medical College, Gujarat, India, in 1990.
Experience:
- Completed internship and residency in internal medicine at Baylor College of Medicine, Houston, earning the title of Outstanding Resident in 1993.
- Undertook fellowships in cardiology (1998) and interventional cardiology (2000) at Cleveland Clinic, Cleveland, where he was also the Chief Interventional Fellow.
- Worked as an interventional cardiologist at the VA Puget Sound Health Care System, Seattle, with an academic appointment at the University of Washington (2000–2003).
- Joined Cleveland Clinic as an interventional cardiologist in 2003, later becoming the Director of the Sones Cardiac Catheterization Laboratories in 2009 and Section Head of Invasive and Interventional Cardiology in 2014.
- Appointed Chairman of the Department of Cardiovascular Medicine at Cleveland Clinic in 2019.
Affiliated Hospitals
Clinical Trials Samir Kapadia is currently running
Transcatheter Valve Repair
for Mitral Regurgitation
This trial tests a new device called Edwards PASCAL that fixes leaky heart valves without surgery. It is for patients who can't have surgery or haven't improved with other treatments. The device helps the valve close better, stopping blood from leaking backward.
Recruiting1 award N/A9 criteria
Cephea Valve System
for Mitral Regurgitation
This trial is testing a new device called the Cephea Mitral Valve System that can fix or replace a damaged heart valve using a thin tube. It aims to help patients with mitral valve disease who need a less invasive treatment than open-heart surgery. The Cephea Mitral Valve System is a new technology developed by Cephea Valve Technologies, aiming to treat severe mitral regurgitation through a less invasive approach.
Recruiting1 award N/A
More about Samir Kapadia
Clinical Trial Related6 years of experience running clinical trials · Led 18 trials as a Principal Investigator · 10 Active Clinical TrialsTreatments Samir Kapadia has experience with
- V-Wave Shunt Placement
- Carillon Mitral Contour System
- Tendyne Mitral Valve System
- MitraClip System
- Intracardiac Echocardiography (ICE)
- Sentinel® Cerebral Protection System
Breakdown of trials Samir Kapadia has run
Mitral Regurgitation
Mitral Valve Regurgitation
Heart Failure
Valvular Heart Disease
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Samir Kapadia specialize in?
Samir Kapadia focuses on Mitral Regurgitation and Mitral Valve Regurgitation. In particular, much of their work with Mitral Regurgitation has involved Stage III patients, or patients who are undergoing treatment.
Is Samir Kapadia currently recruiting for clinical trials?
Yes, Samir Kapadia is currently recruiting for 9 clinical trials in Cleveland Ohio. If you're interested in participating, you should apply.
Are there any treatments that Samir Kapadia has studied deeply?
Yes, Samir Kapadia has studied treatments such as V-Wave Shunt Placement, Carillon Mitral Contour System, Tendyne Mitral Valve System.
What is the best way to schedule an appointment with Samir Kapadia?
Apply for one of the trials that Samir Kapadia is conducting.
What is the office address of Samir Kapadia?
The office of Samir Kapadia is located at: Cleveland Clinic, Cleveland, Ohio 44195 United States. This is the address for their practice at the Cleveland Clinic.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.